הבדלים בין גרסאות בדף "צפוניציד טבע - Cefonicid Teva"

צפוניציד טבע - Cefonicid Teva
התוויות	Treatment of serious bacterial infections caused by microorganisms susceptible to cefonicid. Studies on specimens obtained prior to therapy should be used to determine the susceptibility or the causative organisms to Cefonicid. Therapy with Cefonicid may be initiated pending results of the studies however. Treatment should be adjusted according to study findings. Cefonicid-teva is indicated in the treatment of the infections of the lower respiratory tract urinary tract skin and skin structure bone and joints. In the treatment of the above-mentioned infections the product is particularly used in weak and/or immuno-depressed patients. Surgical prophylaxis: The administration of a single 1 g. dose of Cefonicid-teva before surgery may reduce the incidence of post-operative infections caused by susceptible microorganisms in patients undergoing surgical procedures classified as contaminated or potentially contaminated or in patients in whom infection at the operative site would present a serious risk providing protection during all the surgery period and for about 24 hours following administration. Supplementary doses of Cefonicid-teva may be administered for two additional days to patients undergoing prosthetic arthroplasty. In cesarean section the intra-operative administration of Cefonicid-teva (after the umbilical cord has been clamped) reduces the incidence of post-operative sepsis.

גרסה מ־10:44, 4 באוגוסט 2013

לערכים נוספים הקשורים לנושא זה, ראו את דף הפירושים – צפלוספורין

דרך מתן

מינונים

התוויות נגד

תופעות לוואי

פרמקוקינטיקה

פרמקודינמיקה

תגובות בין-תרופתיות

שימוש בהריון

מאמרים

מידע ברשת

WebMD

@@ שורה 1: / שורה 1: @@
+{{הרחבה|צפלוספורין}}
 {{תרופה
 |שמות נוספים=

צפוניציד טבע - Cefonicid Teva


קבוצה פרמקולוגית (ATC)	"SECOND GENERATION CEPHALOSPORINS"
שם התרופה	"צפוניציד®" (קישור לדף התרופה במאגר משרד הבריאות)
סל הבריאות	כלול
מסגרת הכללה בסל	תרופה מוגבלת לשימוש בבתי חולים או אשפוז יום.
התוויות	Treatment of serious bacterial infections caused by microorganisms susceptible to cefonicid. Studies on specimens obtained prior to therapy should be used to determine the susceptibility or the causative organisms to Cefonicid. Therapy with Cefonicid may be initiated pending results of the studies however. Treatment should be adjusted according to study findings. Cefonicid-teva is indicated in the treatment of the infections of the lower respiratory tract urinary tract skin and skin structure bone and joints. In the treatment of the above-mentioned infections the product is particularly used in weak and/or immuno-depressed patients. Surgical prophylaxis: The administration of a single 1 g. dose of Cefonicid-teva before surgery may reduce the incidence of post-operative infections caused by susceptible microorganisms in patients undergoing surgical procedures classified as contaminated or potentially contaminated or in patients in whom infection at the operative site would present a serious risk providing protection during all the surgery period and for about 24 hours following administration. Supplementary doses of Cefonicid-teva may be administered for two additional days to patients undergoing prosthetic arthroplasty. In cesarean section the intra-operative administration of Cefonicid-teva (after the umbilical cord has been clamped) reduces the incidence of post-operative sepsis.
שם יצרן	LABORATORIO FARMACEUTICO C.T. S.R.L., ITALY
שם בעל הרישום	SALOMON,LEVIN & ELSTEIN LTD